Oncology Institute (DFPH) Equity Average (2020 - 2026)

Oncology Institute (DFPH) has reported Equity Average for 7 consecutive years, with -$16.0 million the latest figure, recorded in Q1 2026.

• Equity Average for Q1 2026 came in at -$16.0 million, down 469.66% year-over-year; the trailing twelve-month figure through Mar 2026 was -$16.0 million (down 469.66% YoY), and the FY2025 annual result was -$6.1 million, down 120.01% from the prior year.
• Equity Average was -$16.0 million for Q1 2026 at Oncology Institute, down from -$14.0 million in the prior quarter.
• Over five years, Equity Average peaked at $128.0 million in Q2 2022 and troughed at -$16.0 million in Q1 2026.
• Average Equity Average over 5 years is $54.2 million, with a median of $49.2 million recorded in 2024.
• Year-over-year, Equity Average soared 213.84% in 2022 and slumped 469.66% in 2026.
• Over 5 years, Equity Average stood at $125.6 million in 2022, then tumbled by 48.68% to $64.4 million in 2023, then tumbled by 85.2% to $9.5 million in 2024, then plunged by 246.79% to -$14.0 million in 2025, then declined by 14.33% to -$16.0 million in 2026.
• Per Business Quant data, the three most recent Equity Average figures were -$16.0 million in Q1 2026, -$14.0 million in Q4 2025, and -$10.6 million in Q3 2025.